Transgene Biotek Ltd
Transgene Biotek Ltd (TRABI) last reported results for the quarter ended Jun 2026, with sales of ₹0.06 crore and net profit of ₹-0.39 crore. Transgene Biotek Ltd’s board meets on 10 Oct 2026. The stock last traded at ₹2.4, a market capitalisation of ₹18.2 crore. Over the past 52 weeks the stock has ranged between ₹1.83 and ₹4.39. Figures are as of 6 Oct 2026 and are not real time.
Transgene Biotek Ltd share price and key metrics
- Current price
- ₹2.4
- Market cap
- ₹18.2 cr
- Book value
- ₹1.11
- ROE
- -17.9%
- ROCE
- -2.36%
- Dividend yield
- 0.00%
- 52w high / low
- 4.39/1.83
Metrics as of 6 Oct 2026. Not real time.
Track Transgene Biotek Ltd
Cruxal reads every Transgene Biotek Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Transgene Biotek Ltd growth and returns
- 10 Years
- 2%
- 5 Years
- 4%
- 3 Years
- 52%
- TTM
- -22%
- 10 Years
- 7%
- 5 Years
- 13%
- 3 Years
- 20%
- TTM
- -24%
- 10 Years
- 0%
- 5 Years
- -11%
- 3 Years
- -16%
- 1 Year
- -41%
- 10 Years
- -23%
- 5 Years
- -30%
- 3 Years
- -10%
- Last Year
- -18%
Transgene Biotek Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹0.06 cr, up 20.0% from ₹0.05 cr a year earlier. Net profit was ₹-0.39 cr, up 9.3% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.06 | 0.08 | 0.08 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 |
| Expenses | 0.13 | 0.17 | 0.62 | 0.18 | 0.13 | 0.1 | 0.33 | 0.12 |
| Operating profit | -0.07 | -0.09 | -0.54 | -0.13 | -0.08 | -0.05 | -0.28 | -0.06 |
| OPM % | -116.67% | -112.50% | -675.00% | -260.00% | -160.00% | -100.00% | -560.00% | -100.00% |
| Other income | 0.04 | 0.04 | 0.04 | 0 | 0 | 0 | 0.15 | 0 |
| Interest | 0.02 | 0.02 | 0.19 | 0.25 | 0.26 | 0.27 | 0.28 | 0.29 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 |
| Profit before tax | -0.07 | -0.09 | -0.71 | -0.43 | -0.39 | -0.37 | -0.46 | -0.39 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net profit | -0.07 | -0.09 | -0.71 | -0.43 | -0.39 | -0.37 | -0.46 | -0.39 |
| EPS (₹) | -0.01 | -0.01 | -0.09 | -0.06 | -0.05 | -0.05 | -0.06 | -0.05 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Transgene Biotek Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.28 | 0.12 | 0.07 | 0 | 0.17 | 0.09 | 0.06 | 0.23 | 0.26 | 0.21 | 0.21 |
| Operating profit | -2.56 | -2.1 | -0.68 | -0.87 | -0.53 | -0.46 | -0.62 | -0.6 | -1.12 | -0.54 | -0.47 |
| OPM % | -914.29% | -1,750.00% | -971.43% | — | -311.76% | -511.11% | -1,033.33% | -260.87% | -430.77% | -257.14% | -223.81% |
| Net profit | -19.86 | -6.44 | -8.79 | -10.96 | -10.43 | -10.4 | -6.01 | -0.66 | -0.68 | -1.65 | -1.61 |
| EPS (₹) | -2.62 | -0.85 | -1.16 | -1.45 | -1.38 | -1.37 | -0.79 | -0.09 | -0.09 | -0.22 | -0.21 |
TTM is the trailing twelve months to the most recent quarter.
Transgene Biotek Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 |
| Reserves | -16.90 | -23.34 | -32.13 | -43.10 | -53.53 | -58.39 | -64.40 | -65.06 | -65.74 | -67.39 |
| Borrowings | 16.01 | 9.84 | 9.14 | 10.33 | 11.33 | 12.01 | 13.11 | 14.00 | 14.52 | 17.14 |
| Other liabilities | 123.18 | 124.28 | 123.77 | 123.75 | 123.31 | 117.71 | 117.87 | 117.62 | 119.54 | 118.14 |
| Total liabilities | 198.06 | 186.55 | 176.55 | 166.75 | 156.88 | 147.10 | 142.35 | 142.33 | 144.09 | 143.66 |
| Fixed assets | 61.16 | 50.97 | 41.10 | 31.20 | 21.32 | 11.40 | 6.45 | 6.36 | 7.96 | 9.63 |
| CWIP | 2.04 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.10 | 0.10 | 0.10 | 0.09 |
| Other assets | 134.86 | 133.71 | 133.58 | 133.68 | 133.69 | 133.73 | 133.93 | 134.00 | 134.16 | 133.94 |
| Total assets | 198.06 | 186.55 | 176.55 | 166.75 | 156.88 | 147.10 | 142.35 | 142.33 | 144.09 | 143.66 |
As reported by the company. Total assets equal total liabilities by construction.
Transgene Biotek Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0.02 | -0.63 | -1.74 | 0.14 | 0.01 | 0.10 | 0.00 | 0.00 | 1.20 | -0.01 |
| Cash from investing | 0.00 | 3.05 | 1.74 | 0.00 | -0.03 | -0.10 | -0.01 | 0.00 | -1.70 | 0.15 |
| Cash from financing | 0.00 | -2.37 | 0.00 | -0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.78 | -0.36 |
| Net cash flow | 0.02 | 0.05 | 0.00 | -0.06 | -0.01 | 0.00 | -0.01 | 0.00 | 0.28 | -0.22 |
| Free cash flow | 0.02 | 2.74 | -0.01 | 0.14 | -0.02 | 0.10 | 0.00 | 0.00 | -0.50 | 0.14 |
| CFO / operating profit | -1% | 30% | 256% | -16% | -2% | -22% | 0% | 0% | -107% | 2% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Transgene Biotek Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | -14.69% | -10.97% | -17.91% | -22.11% | -26.56% | -32.31% | -20.01% | -2.07% | -1.75% | -2.36% |
| Debtor days | 13.04 | 30.42 | 52.14 | — | 21.47 | 40.56 | 60.83 | 15.87 | 14.04 | 17.38 |
| Inventory days | — | 365.00 | 365.00 | 1,460.00 | 121.67 | — | 156.43 | — | — | — |
| Days payable | — | 5,018.75 | 3,528.33 | 13,870.00 | 1,460.00 | — | 1,199.29 | — | — | — |
| Cash conversion cycle | 13.04 | -4,623.33 | -3,111.19 | — | -1,316.86 | 40.56 | -982.02 | 15.87 | 14.04 | 17.38 |
| Working capital days | -14,339.29 | -39,967.50 | -62,519.29 | — | -29,092.65 | -34,593.89 | -57,365.83 | -15,933.04 | -16,509.23 | -21,361.19 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Transgene Biotek Ltd shareholding pattern
Promoters held 23.64% at Sep 2026, broadly unchanged since Sep 2025.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% |
| Public | 76.37% | 76.38% | 76.37% | 76.37% | 76.37% | 76.37% | 76.37% | 76.37% |
| No. of shareholders | 13,307 | 13,583 | 13,475 | 13,461 | 13,545 | 13,767 | 13,817 | 13,775 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When does Transgene Biotek Ltd’s board next meet?
Transgene Biotek Ltd’s board meets on 10 Oct 2026.
- Board meetingApproval of appointment of new statutory auditors
- AGMExtension of time for holding 36th Annual General Meeting
See the full results calendar for every Indian company reporting in the next 30 days.
Transgene Biotek Ltd corporate filings
- Transgene Biotek Limited appoints M/s. Eswara Rao & Co. as new statutory auditors to fill casual vacancyBoard Meetinglow impact
Cruxal's analysis: Transgene Biotek Limited announced on October 10, 2026, the appointment of M/s. Eswara…
Read the full analysis - Statement of Deviation & Variation filed for Transgene Biotek Ltd, dated 30-09-2026Company Updatelow impact
Cruxal's analysis: Transgene Biotek Ltd has submitted a regulatory disclosure regarding deviation and…
Read the full analysis - Transgene Biotek Ltd files compliance intimation post-quarter end, no financial or operational updates providedOtherslow impact
Cruxal's analysis: The company has submitted a compliance report as per regulation 57(5) after the end of…
Read the full analysis - Compliance -57(4)Otherslow impact
- Transgene Biotek Limited confirms it does not qualify as a Large Corporate under SEBI criteria, indicating no immediate regulatory compliance obligations related to debt issuance thresholds.Otherslow impact
Cruxal's analysis: Transgene Biotek Limited, a small-cap company with a market capitalization of…
Read the full analysis - Compliance Certificate 7(3) as on 30-09-2026.Company Updatelow impact
- Compliances Certificate under Reg. 74(5)Company Updatelow impact
- Transgene Biotek Limited schedules Board meeting on October 10, 2026, to consider appointment of new statutory auditors, indicating potential corporate governance and compliance updates.Board Meetinglow impact
Cruxal's analysis: Transgene Biotek Limited has announced a Board meeting scheduled for October 10, 2026…
Read the full analysis - Transgene Biotek Limited receives ROC approval for 3-month extension to hold 36th Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Transgene Biotek Limited has been granted a total extension of three months by the…
Read the full analysis - Transgene Biotek Limited Announces Immediate Resignation of Statutory Auditors M/s Vasavi & Co.Company Updatehigh impact
Cruxal's analysis: Transgene Biotek Limited has disclosed the immediate resignation of its statutory…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
- Closure of Trading WindowInsider Trading / SASTlow impact
- Transgene Biotek Ltd: Newspaper Publication of Financial Results NoticeCompany Updatelow impact
Cruxal's analysis: Transgene Biotek Ltd has issued a mandatory newspaper publication regarding the…
Read the full analysis - Transgene Biotek Limited Reports Continued Financial Losses for Quarter Ended June 2026Board Meetinglow impact
Cruxal's analysis: Transgene Biotek Limited reported a net loss of 38.90 lakh for the quarter ended 30th…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.